Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Citrus compound could be the next workout and brain booster

NCT ID NCT06672952

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a supplement called glucosyl-hesperidin (CitraPeak), derived from citrus, can improve exercise performance, blood flow, recovery, and cognitive function in 60 recreationally active adults aged 18-50. Participants will take either 200 mg, 400 mg, or a placebo daily for 8 weeks, with measurements of aerobic capacity, power output, blood flow, and self-reported mood and stress. The goal is to see if this natural compound offers a safe, effective boost for active people.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glucosyl-hesperidin (CitraPeak) dietary supplement
What this could lead to
If it works, this could point toward a natural supplement that boosts exercise performance, recovery, and mental focus.
What could go wrong
This is an early-stage, small trial (60 people) testing a supplement, not a drug. Results may not apply to everyone, and benefits could be minor or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who are between 18 - 50 years of age 2. Body mass index values will range from \>25.0 \< 30.0 kg/m2 3. The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg/m2 4. Free-living and independent 5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders 6. Willingness to maintain consistent sleep duration the evening before study visits 7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures 8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months Exclusion Criteria: 1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months 2. Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease 3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals 4. Has liver disease or some form of clinically diagnosed hepatic impairment 5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \> 126 mg/dL) 6. Diagnosed with or is being treated for some form of thyroid disease 7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year 8. Diagnosed with some form of immune disorder (i.e., HIV/AIDS) 9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). 10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) 11. Positive medical history for any neurological condition or neurological disease 12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) 13. Current smoker (average of \> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine 14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc. 15. Participants who are lactating, pregnant or planning to become pregnant 16. Have a known sensitivity or allergy to any of the study products 17. History of alcohol or substance abuse in the 12 months prior to screening 18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol 19. Any orthopedic limitation that would prevent participation in a general fitness program 20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood flow are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lindenwood University

    RECRUITING

    Saint Charles, Missouri, 63301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.